28179-47-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Aminoisophthalic acid monomethyl ester is used as an intermediate in the synthesis of pharmaceuticals for its ability to participate in various chemical reactions, contributing to the development of new drug molecules.
Used in Dye Industry:
In the dye industry, 5-Aminoisophthalic acid monomethyl ester is utilized as a building block for the production of dyes, capitalizing on its reactivity to create a range of colorants for different applications.
Used in Polymer Materials Industry:
5-Aminoisophthalic acid monomethyl ester is employed as an intermediate in the creation of polymer materials, leveraging its chemical properties to enhance the properties of the resulting polymers, such as their stability, durability, or specific functional characteristics.

InChI:InChI=1/C9H9NO4/c1-14-9(13)6-2-5(8(11)12)3-7(10)4-6/h2-4H,10H2,1H3,(H,11,12)

Upstream product

• 1955-46-0 5-nitro-1,3-benzenedicarboxylic acid, monomethyl ester 

Downstream Products

• 161796-10-7 3-bromo-5-(methoxycarbonyl)benzoic acid 
• 153203-57-7 3-chloro-5-(methoxycarbonyl)benzoic acid 
• 900799-65-7 5-benzyloxycarbonylamino-isophthalic acid monomethyl ester 
• 1373965-82-2 monomethyl 5-(n-propylamino)isophthalate 
• 1373965-83-3 monomethyl 5-(n-pentylamino)isophthalate 
• 1429636-94-1 C₂₂H₃₅N₇O₈S*C₂HF₃O₂ 
• 73334-07-3 iopromide 
• 325981-11-1 3-[(3-Chlorophenyl)carbonylamino]-5-(methoxycarbonyl)benzoic Acid 
• 93116-99-5 3-iodo-5-(methoxycarbonyl)benzoic acid 

Relevant academic research and scientific papers

The first ready-to-use benzene-based heterotrifunctional cross-linker for multiple bioconjugation

The synthesis and applications of the first water-soluble benzene derivative bearing a set of three different and orthogonal bioconjugatable groups (aminooxy, azido and thiol) are described. The combined use of a 5-amino isophthalic acid scaffold and unusual acid-labile protecting groups for temporarily masking aminooxy and thiol moieties has enabled the development of a highly convergent approach towards the synthesis of such a trivalent bioconjugation platform in good yields. The potential utility of this ready-to-use cross-linking reagent for creating complex and fragile tri-component (bio)molecular systems was illustrated through (1) the rapid preparation of a three-colour FRET cascade with valuable spectral properties and (2) the luminescent/fluorescent labelling of peptides and peptide- oligonucleotide conjugates. Thus, such (bio)molecular assemblies were readily obtained via a three-step process or in a one-pot manner, both involving oxime ligation, thiol-alkylation (SN2 or Michael addition) and copper-catalysed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reactions.

Molecular chirality and chiral capsule-type dimer formation of cyclic triamides via hydrogen-bonding interactions

Chiral properties of bowl-shaped cyclic triamides bearing functional groups with hydrogen-bonding ability were examined. Chiral induction of cyclic triamide 3a was observed by addition of chiral amine in solution, and chiral separation was achieved by sim

PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MIP-1 of formula (I) : or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE

A series of N-((2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-(3-methoxybenzylamino)-butan-2-yl)benzamides has been synthesized as BACE inhibitors. A variety of P2 and P3 substituents has been explored, and these efforts have culminated in the identification

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Novel phenylcarboxyamides as beta-secretase inhibitors

There is provided a series of novel phenylcarboxyamides of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and Y as defined herein, their pharmaceutical compositions and

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof

The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS

There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Rigid macrocyclic triamides as anion receptors: Anion-dependent binding stoichiometries and 1H chemical shift changes

The cyclic triamide of 3′-amino-3-biphenylcarboxlic acid is readily synthesized in a stepwise manner and represents a novel class of anion receptors with a large central cavity. This macrocycle binds more strongly to tetrahedral anions than spherical or p